Biomedical subjects

R Pilkington

Publications and source records attributed to R Pilkington.

11 recordsLinked to original sources

PubMed1990

Nosocomial lower respiratory tract infections in surgical wards.

A six month prospective study of nosocomial lower respiratory tract infection was conducted in four general surgery wards and one urological surgery ward. Thirty eight cases were identified, representing 1% of the surgical admissions to these wards. Twenty eight of the infections followed abdominal surgery. Six patients died, five of whom had pre-existing cardiorespiratory disease. Potential pathogens were isolated in 21 patients, the commonest organisms being Streptococcus pneumoniae and Haemophilus influenzae.

Adult↗

PubMed1988

In-vitro assessment of lomefloxacin (SC-47111)--a new quinolone derivative.

The activity of lomefloxacin (SC-47111) was studied in vitro against 500 clinical isolates. Comparison was made with enoxacin and ciprofloxacin. Lomefloxacin was comparable in activity to enoxacin, but less active than ciprofloxacin. Most Gram-negative bacilli were susceptible, including several multi-resistant strains. Pseudomonas aeruginosa showed variable susceptibility. Streptococci, including Streptococcus pneumoniae, were generally the least susceptible organisms.

Anti-Bacterial Agents↗

PubMed1986

Clinical evaluation of treatment with ciprofloxacin.

Explore the source record for details and available documents.

Abdomen↗

PubMed1986

In vitro assessment of CI-934--a new quinolone derivative.

CI-934 is a new broad-spectrum fluoroquinolone. We have studied its in vitro activity against 203 bacteria and compared it with ciprofloxacin, enoxacin, ampicillin, cefuroxime, cefotaxime, gentamicin, vancomycin and erythromycin. Against Gram-negative pathogens CI-934 showed broad-spectrum activity comparable to enoxacin. Of more interest is its superior activity against Gram-positive bacteria, especially Streptococcus pneumoniae and enterococci. This was further studied by observing its activity in comparison with ampicillin in in vitro kinetic studies. CI-934 was either equally or more rapidly bactericidal than ampicillin at concentrations of 1, 4, and 16 X MIC. On the basis of these findings further in vivo studies appear justified.

Anti-Bacterial Agents↗

PubMed1985

Aetiology and outcome of severe community-acquired pneumonia.

Between January 1972 and December 1981, 50 patients with severe community-acquired pneumonia were admitted to the intensive care unit of a district general hospital. A causal pathogen was identified in 41 cases (82%). Streptococcus pneumoniae (16 cases), Legionella pneumophila (15 cases) and Staphylococcus aureus (5 cases) were the commonest. Assisted ventilation was required in 44 patients, of whom 25 died (57%). All 5 patients with staphylococcal pneumonia and 12(75%) with pneumococcal pneumonia died. Only 5 (33%) with Legionnaires' disease died. Mortality was significantly associated with age. Recommendations for the management of severe pneumonia are made.

Adult↗

PubMed1981